Erbe introduces VIO® 3n & VIO® seal: Tailored electrosurgical generators for high-performance workflows
With the introduction of the VIO® 3n, Erbe Elektromedizin GmbH expands its established VIO® 3 family with a new generation of electrosurgical generators, specifically tailored to different medical specialties and procedural requirements. The portfolio is further enhanced by the VIO® seal, the first VIO® generator fully dedicated to bipolar applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425843193/en/
VIO 3n Fire
Five configurations for precise surgical and endoscopic applications
With over 100 years of experience in electrosurgery, Erbe continues to innovate with the introduction of five new VIO® 3n configurations: Fire, Water, Metal, Timber, and Stone. Each configuration is designed to meet the unique demands of different surgical and endoscopic procedures, providing preprogrammed CUT, COAG, and dissection settings that enhance efficiency and reduce complexity. The VIO® 3n features trusted Erbe electrosurgical modes such as endoCUT®, preciseSECT, and pulsedAPC, ensuring reproducible tissue effects across specialties, also introducing our new mode endoCUT® U, developed for “underwater” applications.
Beyond precise tissue effect adjustment, the VIO® 3n prioritizes intuitive usability: its interface with stepGUIDE supports surgical teams with logical menu navigation and real-time notifications, simplifying setup and operation. Additionally, the generator seamlessly integrates with other Erbe units, such as APC 3 and IES 3, as well as Erbe instruments and accessories allowing flexible adaptation to existing workstations.
VIO® seal: The first VIO® generator for bipolar applications
As a specialized solution for bipolar electrosurgical procedures, the VIO® seal is a significant addition to the Erbe portfolio. Designed for use with TriSect rapide®, BiClamp® and standard bipolar instruments, the unit can function as a standalone solution or in combination with the VIO® 3n as well as existing installed bases like the VIO® D and S series. Featuring digital instrument recognition, it aligns perfectly with surgical workflows.
A key feature: when paired with another VIO® generator, the VIO® seal enables simultaneous bipolar activation, expanding the possibilities of surgical procedures.
A future-proof electrosurgical solution built to fit various clinical demands
With the launch of the VIO® 3n and VIO® seal, Erbe takes another step toward becoming a comprehensive solution provider. The combination of tailored configurations, high-performance workflows, and trusted Erbe technology creates a platform designed to meet the specific needs of various medical specialties.
“After more than 100 years of electrosurgery and over 100,000 VIO® electrosurgical generators sold, Erbe is launching the next generation – the VIO® 3n,” explains Dr. Helmut Scherer, Chief Technology Officer of the Erbe Group. “With the VIO® 3n, the successful operating concept of the VIO® 3 is transferred to the next technology generation and made available for various medical disciplines.”
The new systems will be available in the CE market and CE related countries from April 2025.
About Erbe Elektromedizin
Erbe Elektromedizin develops, manufactures, and distributes surgical instruments and devices worldwide, while providing services for professional use of these products in a diverse range of medical disciplines. Surgeons, OR teams and patients around the world rely on Erbe medical technology. The surgical instruments and devices find use in almost all specialist areas. They are based on electrosurgery combined with other Erbe technologies. Hybrid solutions enable us to provide new, innovative applications in medicine.
Fields of activity
- Imaging
- Endoscopy
- Electrosurgery
- Plasma surgery
- Thermofusion
- Hydrosurgery
- Cryo technology
An international network
- 20 international sales and service units
- 5 production sites
- Erbe is active in 110 international markets.
The Erbe workforce
- 2,100 employees worldwide
- Some 1,100 of them in Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20250425843193/en/
Contacts
Erbe Elektromedizin GmbH
Waldhoernlestrasse 17
72072 Tuebingen
erbe-med.com -
https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.erbe-med.co
m%2F&esheet=54239766&newsitemid=20250425843193&lan=en-US&anchor=erbe-med.com&ind
ex=1&md5=388b47eab0c5becafa55f448f8f57000
info@erbe-med.com
David Malecki
Phone +49 7071 755-316
david.malecki@erbe-med.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTIMindtree, Eurobank and Fairfax Digital Services Collaborate to Build Digital Innovation Hub in Cyprus16.5.2025 10:00:00 EEST | Press release
LTIMindtree [NSE: LTIM, BSE: 540005], a global technology consulting and digital solutions company, has announced the opening of its Digital Innovation Hub at the Research and Innovation Hub of CYENS Center of Excellence. The LTIMindtree Digital Innovation Hub will enable ideation, co-creation and implementation of Advanced Digital Solutions for Eurobank, Fairfax and other EU customers and aligns with the strategic vision of the Cyprus Government to strengthen Cyprus’ role as a regional tech and innovation hub, triggering unique cross-border opportunities for tech collaborations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515054331/en/ Srini Rao EVP & Chief Business Officer- Europe, LTIMindtree | Mr. Nikodemos Damianou, Deputy Minister of Research and Innovation, Govt of Cyprus | Mr. Fokion Karavias, Group CEO, EUROBANK Group | Mr. Sanjay Tugnait, President & CEO, Fairfax Digital along with other esteemed client execu
ROYC Acts as the Structuring and Financial Technology Partner for Riverside for European Wealth Access Fund16.5.2025 09:30:00 EEST | Press release
ROYC, the leading provider of complete private markets operating systems, announces the structuring of a new access fund for Private Wealth launched in collaboration with The Riverside Company. The Riverside Company is a global private equity firm focused on investing in growing businesses valued at up to $400 million. Since its founding in 1988, Riverside has made more than 1,000 investments and today has over $12 billion in assets under management. The firm's international private equity and structured capital portfolios include more than 140 companies. The Riverside’s proven investment strategy of acquiring and developing high-potential European SMEs in resilient, growth-oriented sectors, including technology and software, healthcare, advanced manufacturing and consumer products. “This fund represents a unique opportunity for wealth investors to access value creation generally reserved for institutional investors,” says Karsten Langer, Managing Partner at Riverside Europe and contin
Rimini Street Announces Upcoming 2025 Investor Conference Schedule15.5.2025 23:51:00 EEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support and innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced that Michael L. Perica, chief financial officer, and Dean Pohl, vice president, treasurer and investor relations, will be presenting and meeting with investors one-on-one and in small group meetings at the following conferences: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250515374696/en/ Rimini Street Announces Upcoming 2025 Investor Conference Schedule May 28, 2025: Craig-Hallum 22nd Annual Institutional Investor Conference, Minneapolis May 29, 2025: TD Cowen 53rd Annual TMT Conference, New York City Fireside Chat: 1:15 pm Eastern, webcast link June 24-26, 2025: Roth 15th Annual London Conference, London To schedule a meeting please contact your salesperson or Rimini Street Investor Relations at IR@rimin
Incyte Announces FDA Approval of Zynyz ® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States15.5.2025 21:30:00 EEST | Press release
Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz® (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508024371/en/ Zynyz logo "The FDA approval of Zynyz marks a pivotal moment, bringing effective combination and monotherapy treatment options to patients with advanced anal cancer after decades of limited innovation," said Hervé Hoppenot,
DDC Announces Record 2024 Growth and Strategic Bitcoin Reserve Initiative in Shareholder Letter by Founder & CEO Norma Chu15.5.2025 21:23:00 EEST | Press release
DDC Enterprise Ltd. (NYSEAM: DDC), today released its 2024 full year results alongside a Shareholder Letter from Founder, Chairwoman, and CEO Norma Chu, underscoring the company’s positive financial performance and unveiling a pioneering Bitcoin accumulation strategy poised to redefine long-term value creation. To Our Valued Shareholders, 2024 was a year of transformative growth and strategic milestones for DDC. I am thrilled to share that we not only met our financial forecasts but exceeded expectations, delivering strong performance across key metrics while laying the groundwork for an even more exciting future. As we enter 2025, our momentum is accelerating, driven by disciplined execution and a bold new chapter in our corporate strategy. 2024 Financial & Operational Highlights Revenue Growth: USD 37.4 million, a 33% year-over-year increase, propelled by the strategic acquisition of U.S. brands and sustained resilience in our core China operations. Margin Expansion: Gross profit mar
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom